23:52 , Jan 14, 2019 |  BC Extra  |  Preclinical News

ClostraBio identifies gut bacteria species that prevents milk allergy

A team led by Cathryn Nagler, a food allergy professor at the University of Chicago and president and co-founder of ClostraBio Inc. (Chicago, Ill.), has identified a bacterial species that could prevent allergic reaction to...
17:59 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Celgene invested $30M in NantCell weeks before BMS bid

NantCell said Celgene Corp. (NASDAQ:CELG) invested $30 million through a crossover round, valuing NantCell at $4 billion. The investment, which closed Dec. 19, brings Celgene's total investment in the immunotherapy company to $105 million for...
17:41 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Autolus' dual targeting CAR T safe in Phase I/II data for hematological malignancies

Autolus Therapeutics plc (NASDAQ:AUTL) reported preliminary data from a pair of open-label, U.K. Phase I/II trials showing that AUTO3 had a manageable safety profile and led to responses among patients with hematological malignancies. AUTO3 comprises...
00:44 , Jan 11, 2019 |  BC Extra  |  Preclinical News

UW team builds protein that avoids IL-2 toxicities, forms Neoleukin to develop

University of Washington researchers published a Nature paper Wednesday detailing the construction of a synthetic protein that selectively binds to IL-2 to avoid toxicities that have previously overshadowed interest in the receptor as a therapeutic...
22:46 , Jan 6, 2019 |  BC Extra  |  Financial News

Celgene invested $30M in NantCell weeks before BMS bid

NantCell said Celgene Corp. (NASDAQ:CELG) invested $30 million through a crossover round, valuing NantCell at $4 billion. The investment, which closed Dec. 19, brings Celgene's total investment in the immunotherapy company to $105 million for...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
20:48 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Cytokine release syndrome (CRS) Mouse studies suggest down-regulating catecholamines with NPPA or the TYH inhibitor Demser could help treat CRS. In a mouse model of colon cancer with Clostridium novyi -NT-induced CRS, C. novyi...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
23:31 , Dec 12, 2018 |  BC Extra  |  Preclinical News

Repurposing hypertension drugs to block cytokine release syndrome

Johns Hopkins University School of Medicine researchers showed that hypertension drug Demser metyrosine and an endogenous peptide in testing for hypertension could prevent cytokine release syndrome, a toxicity associated with immunotherapies, without compromising efficacy. Cytokine...
16:11 , Dec 12, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model could help predict immune responses to vaccines. Generation and use of the model involves: placing a single layer of donor-derived human umbilical vein endothelial cells (HUVECs) over...